<DOC>
	<DOC>NCT02058940</DOC>
	<brief_summary>The purpose of this study is to assess the feasibility of exenatide infusion for the treatment of high blood sugars following acute brain injury.</brief_summary>
	<brief_title>Intravenous Exenatide in Patients With Acute Brain Injury</brief_title>
	<detailed_description />
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Adults ≥18 years Acute brain injury resulting in admission to the Neurosciences Intensive Care Unit for an anticipated length of stay &gt;48 hours Two Blood glucose concentrations &gt; 150 mg/dL and ≤300 mg/dL Informed consent obtained via proxy Pregnant (verified by urine or serum pregnancy test within 24 hours of initiation of infusion) or lactating females Type 1 diabetes mellitus History of pancreatitis or risk factors for acute pancreatitis (i.e ethanol abuse, gall stones) Renal insufficiency defined as creatinine clearance (CrCL) &lt; 45 mL/min Known history of gastroparesis History of surgery on stomach, esophagus or duodenum Diabetic Ketoacidosis or Hyperosmolar Hyperglycemic Nonketotic Syndrome Concurrent steroid use or planned postoperative steroid use History of organ transplantation Brain death or suspected imminent brain death within the next 72 hours Refractory intracranial hypertension defined as intracranial pressure (ICP) &gt; 25 mmHg for greater than 15 minutes and refractory to medical intervention Currently enrolled in another investigational drug or device protocol Insulin infusion within 3 hours of study drug administration or confirmed long acting insulin or sulfonylurea use prior to admission within 24 hours of study drug administration Known allergy to exenatide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>